Centessa Pharmaceuticals plc Logo

Centessa Pharmaceuticals plc

Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.

CNTA | US

Overview

Corporate Details

ISIN(s):
US1523091007
LEI:
Country:
United States of America
Address:
3RD FLOOR, ALTRINCHAM, CHESHIRE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients with unmet medical needs. The company leverages a data-driven Research & Development model to advance a portfolio of innovative assets. Its lead program is a potential best-in-class orexin receptor 2 (OX2R) agonist being developed for the treatment of sleep-wake disorders. The company's pipeline also includes programs targeting other conditions, such as hemophilia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Centessa Pharmaceuticals plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Centessa Pharmaceuticals plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Centessa Pharmaceuticals plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America OGEN
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP
ORAMED PHARMACEUTICALS INC. Logo
Develops oral drug delivery systems to convert injectable drugs, like insulin, into capsules.
United States of America ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.